The association of sex steroid hormone concentrations with non-alcoholic fatty liver disease and liver enzymes in US men.
estradiol
hepatic steatosis
non-alcoholic fatty liver disease
sex hormone-binding globulin
testosterone
Journal
Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
21
05
2020
revised:
10
08
2020
accepted:
17
08
2020
pubmed:
30
8
2020
medline:
22
6
2021
entrez:
30
8
2020
Statut:
ppublish
Résumé
This study aimed to analyse the association of sex hormone levels with liver enzyme levels and non-alcoholic fatty liver disease (NAFLD) in a nationally representative sample of men. A total of 919 men from the US National Health and Nutrition Examination Study (NHANES) III were included in this cross-sectional analysis of data from 1988 to 1991. We used existing data on serum total and free testosterone, total and free estradiol, androstanediol glucuronide (AAG) and sex steroid-binding globulin (SHBG), and estimated their associations with aspartate aminotransferase (AST), and alanine aminotransferase (ALT) and NAFLD, as determined using ultrasound, after adjusting for possible confounders including age, race, smoking, alcohol, physical activity, waist circumference and steroid hormones. Lower total testosterone (TT) and higher free estradiol were associated with higher odds of NAFLD after adjusting for confounders including the other sex hormones. Lower TT was associated with higher odds of elevated AST, but not ALT. Free testosterone, total estradiol, SHBG and AAG were not associated with NAFLD or liver enzymes. This study supports an inverse association between TT concentration and NAFLD in men independent of other sex hormones (SHBG, AAG and estradiol) and known risk factors, such as obesity, age and lifestyle. Exploration of whether TT might be a non-invasive marker for NAFLD diagnosis is warranted.
Sections du résumé
BACKGROUND & AIMS
This study aimed to analyse the association of sex hormone levels with liver enzyme levels and non-alcoholic fatty liver disease (NAFLD) in a nationally representative sample of men.
METHODS
A total of 919 men from the US National Health and Nutrition Examination Study (NHANES) III were included in this cross-sectional analysis of data from 1988 to 1991. We used existing data on serum total and free testosterone, total and free estradiol, androstanediol glucuronide (AAG) and sex steroid-binding globulin (SHBG), and estimated their associations with aspartate aminotransferase (AST), and alanine aminotransferase (ALT) and NAFLD, as determined using ultrasound, after adjusting for possible confounders including age, race, smoking, alcohol, physical activity, waist circumference and steroid hormones.
RESULTS
Lower total testosterone (TT) and higher free estradiol were associated with higher odds of NAFLD after adjusting for confounders including the other sex hormones. Lower TT was associated with higher odds of elevated AST, but not ALT. Free testosterone, total estradiol, SHBG and AAG were not associated with NAFLD or liver enzymes.
CONCLUSIONS
This study supports an inverse association between TT concentration and NAFLD in men independent of other sex hormones (SHBG, AAG and estradiol) and known risk factors, such as obesity, age and lifestyle. Exploration of whether TT might be a non-invasive marker for NAFLD diagnosis is warranted.
Identifiants
pubmed: 32860311
doi: 10.1111/liv.14652
pmc: PMC10115140
mid: NIHMS1881875
doi:
Substances chimiques
Gonadal Steroid Hormones
0
Testosterone
3XMK78S47O
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
300-310Subventions
Organisme : NCI NIH HHS
ID : P30 CA006973
Pays : United States
Informations de copyright
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
World J Gastroenterol. 2015 Oct 21;21(39):11053-76
pubmed: 26494962
Clin Chem. 2001 Jan;47(1):139-42
pubmed: 11148194
J Gastroenterol Hepatol. 2015 Jul;30(7):1211-6
pubmed: 25708291
Hepatology. 2018 Jan;67(1):328-357
pubmed: 28714183
Cancer Causes Control. 2011 Aug;22(8):1141-51
pubmed: 21678033
Aliment Pharmacol Ther. 2015 Jan;41(1):65-76
pubmed: 25376360
J Spinal Cord Med. 2016 Jul;39(4):443-9
pubmed: 25614040
J Steroid Biochem. 1982 Jun;16(6):801-10
pubmed: 7202083
BJU Int. 2005 Jul;96(1):77-82
pubmed: 15963125
Vital Health Stat 1. 1994 Jul;(32):1-407
pubmed: 7975354
Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12735-40
pubmed: 11070087
Clin Gastroenterol Hepatol. 2015 Sep;13(9):1686-93.e2
pubmed: 25592661
Metabolism. 2016 Aug;65(8):1080-6
pubmed: 26775559
Semin Liver Dis. 2008 Nov;28(4):339-50
pubmed: 18956290
Ulster Med J. 2012 Jan;81(1):30-6
pubmed: 23536736
Eur J Gastroenterol Hepatol. 2015 Sep;27(9):1069-73
pubmed: 26062079
Med Sci Sports Exerc. 1993 Jan;25(1):71-80
pubmed: 8292105
J Hepatol. 2006 Jun;44(6):1196-207
pubmed: 16618516
JAMA. 2015 Jun 9;313(22):2263-73
pubmed: 26057287
Am J Epidemiol. 2013 Jul 1;178(1):38-45
pubmed: 23703888
Ann Hepatol. 2017 May - Jun 2017;16(3):382-394
pubmed: 28425408
CMAJ. 2005 Mar 29;172(7):899-905
pubmed: 15795412
J Clin Endocrinol Metab. 2004 Jan;89(1):61-70
pubmed: 14715828
Clin Gastroenterol Hepatol. 2021 Feb;19(2):400-402.e2
pubmed: 31812658
BMC Gastroenterol. 2012 Jun 12;12:69
pubmed: 22691278
Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1509-10
pubmed: 12433739
Hepatology. 2005 Jul;42(1):44-52
pubmed: 15895401
J Clin Endocrinol Metab. 1999 Oct;84(10):3666-72
pubmed: 10523012
J Urol. 2017 Apr;197(4):1121-1126
pubmed: 27789218
Clin Gastroenterol Hepatol. 2021 Jan;19(1):61-71.e15
pubmed: 32360810
Cancer Epidemiol Biomarkers Prev. 2002 Oct;11(10 Pt 1):1065-71
pubmed: 12376508